Inactivating mutations and loss of heterozygosity in the TRAF3 locus have been reported in a significant proportion of myeloma patients, suggesting that TRAF3 may function as a tumor suppressor [12], [13]. This evidence concerns the gene TRAF3 and plasma cell myeloma.